Aytu Biopharma, INC: insider trades · United States · SEC (Form 4)

About Aytu Biopharma, INC

Aytu BioPharma, Inc. is a U.S.-based specialty pharmaceutical company listed on the Nasdaq Capital Market in the United States under the ticker AYTU. From an equity analyst perspective, it is best characterized as a small-cap commercial-stage biopharma company that combines branded prescription products with a focused central nervous system (CNS) strategy. The company’s headquarters are in Denver, Colorado. Aytu was originally incorporated as Rosewind Corporation in 2002, later reincorporated in Delaware in 2015, and renamed Aytu BioPharma, Inc. in 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) The current strategic narrative is centered on CNS medicines, particularly major depressive disorder (MDD) and ADHD. Aytu’s most important recent growth driver is EXXUA (gepirone) extended-release tablets, a novel first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for adults with MDD. The company emphasizes EXXUA’s differentiated clinical profile, including the absence of a label warning for sexual dysfunction, which may support positioning in a large and highly competitive U.S. antidepressant market. In June 2025, Aytu entered into an exclusive commercialization agreement for EXXUA in the United States and subsequently launched the product as the centerpiece of its commercial strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) Alongside EXXUA, Aytu retains legacy and supporting product lines that help diversify revenue. Its ADHD portfolio includes Adzenys XR-ODT, indicated for patients six years and older, and Cotempla XR-ODT. The company also commercializes Karbinal, a 12-hour carbinoxamine oral suspension for allergy symptoms, as well as the pediatric fluoride/vitamin prescription brands Poly-Vi-Flor and Tri-Vi-Flor. These products give Aytu a mix of higher-growth CNS assets and more mature pediatric/allergy franchises. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001385818/000143774925031722/aytuars.pdf)) Competitive positioning remains challenging. Aytu operates in therapeutic areas dominated by large branded pharmaceutical competitors and, in several cases, subject to generic pressure. The company has therefore been reshaping its portfolio and focusing capital on commercialization rather than broad clinical development. Recent milestones include the June 2025 equity raise, the EXXUA commercialization transaction, the company’s launch execution in late 2025, and international commercialization arrangements for Adzenys and Cotempla, including Canada. For investors in French-speaking markets, AYTU is a high-risk, catalyst-driven pharmaceutical name whose valuation will likely depend on EXXUA uptake, preservation of legacy product cash flows, and disciplined capital allocation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1385818/000143774925029723/aytu20250630c_10k.htm?utm_source=openai))